These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 17261171)
41. Antibody-mediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the potency of chemotherapy. Mårlind J; Kaspar M; Trachsel E; Sommavilla R; Hindle S; Bacci C; Giovannoni L; Neri D Clin Cancer Res; 2008 Oct; 14(20):6515-24. PubMed ID: 18927291 [TBL] [Abstract][Full Text] [Related]
42. Modulation of established murine collagen-induced arthritis by a single inoculation of short-term lipopolysaccharide-stimulated dendritic cells. Salazar L; Aravena O; Abello P; Escobar A; Contreras-Levicoy J; Rojas-Colonelli N; Catalán D; Aguirre A; Zúñiga R; Pesce B; González C; Cepeda R; Cuchacovich M; Molina MC; Salazar-Onfray F; Delgado M; Toes RE; Aguillón JC Ann Rheum Dis; 2008 Sep; 67(9):1235-41. PubMed ID: 18056756 [TBL] [Abstract][Full Text] [Related]
43. Arthritogenic T cell epitope in glucose-6-phosphate isomerase-induced arthritis. Iwanami K; Matsumoto I; Tanaka Y; Inoue A; Goto D; Ito S; Tsutsumi A; Sumida T Arthritis Res Ther; 2008; 10(6):R130. PubMed ID: 18992137 [TBL] [Abstract][Full Text] [Related]
44. Important role of interleukin-3 in the early phase of collagen-induced arthritis. Brühl H; Cihak J; Niedermeier M; Denzel A; Rodriguez Gomez M; Talke Y; Goebel N; Plachý J; Stangassinger M; Mack M Arthritis Rheum; 2009 May; 60(5):1352-61. PubMed ID: 19404955 [TBL] [Abstract][Full Text] [Related]
45. Prophylactic but not therapeutic activity of a monoclonal antibody that neutralizes the binding of VEGF-B to VEGFR-1 in a murine collagen-induced arthritis model. Mould AW; Scotney P; Greco SA; Hayward NK; Nash A; Kay GF Rheumatology (Oxford); 2008 Mar; 47(3):263-6. PubMed ID: 18204088 [TBL] [Abstract][Full Text] [Related]
46. Targeting Extracellular Vesicles to the Arthritic Joint Using a Damaged Cartilage-Specific Antibody. Topping LM; Thomas BL; Rhys HI; Tremoleda JL; Foster M; Seed M; Voisin MB; Vinci C; Law HL; Perretti M; Norling LV; Azevedo HS; Nissim A Front Immunol; 2020; 11():10. PubMed ID: 32117219 [TBL] [Abstract][Full Text] [Related]
47. Herpesvirus entry mediator-Ig treatment during immunization aggravates rheumatoid arthritis in the collagen-induced arthritis model. Pierer M; Schulz A; Rossol M; Kendzia E; Kyburz D; Haentzschel H; Baerwald C; Wagner U J Immunol; 2009 Mar; 182(5):3139-45. PubMed ID: 19234211 [TBL] [Abstract][Full Text] [Related]
48. An engineered GM-CSF-CCL2 fusokine is a potent inhibitor of CCR2-driven inflammation as demonstrated in a murine model of inflammatory arthritis. Rafei M; Berchiche YA; Birman E; Boivin MN; Young YK; Wu JH; Heveker N; Galipeau J J Immunol; 2009 Aug; 183(3):1759-66. PubMed ID: 19592643 [TBL] [Abstract][Full Text] [Related]
49. A human mAb specific to oncofetal fibronectin selectively targets chronic skin inflammation in vivo. Trachsel E; Kaspar M; Bootz F; Detmar M; Neri D J Invest Dermatol; 2007 Apr; 127(4):881-6. PubMed ID: 17185984 [TBL] [Abstract][Full Text] [Related]
50. Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Carnemolla B; Borsi L; Balza E; Castellani P; Meazza R; Berndt A; Ferrini S; Kosmehl H; Neri D; Zardi L Blood; 2002 Mar; 99(5):1659-65. PubMed ID: 11861281 [TBL] [Abstract][Full Text] [Related]
51. Targeting of viral interleukin-10 with an antibody fragment specific to damaged arthritic cartilage improves its therapeutic potency. Hughes C; Sette A; Seed M; D'Acquisto F; Manzo A; Vincent TL; Lim NH; Nissim A Arthritis Res Ther; 2014 Jul; 16(4):R151. PubMed ID: 25029910 [TBL] [Abstract][Full Text] [Related]
52. The antibody-mediated targeted delivery of interleukin-10 inhibits endometriosis in a syngeneic mouse model. Schwager K; Bootz F; Imesch P; Kaspar M; Trachsel E; Neri D Hum Reprod; 2011 Sep; 26(9):2344-52. PubMed ID: 21705369 [TBL] [Abstract][Full Text] [Related]
53. Selective targeted delivery of the TNF-alpha receptor p75 and uteroglobin to the vasculature of inflamed tissues: a preliminary report. Ventura E; Balza E; Borsi L; Tutolo G; Carnemolla B; Castellani P; Zardi L BMC Biotechnol; 2011 Nov; 11():104. PubMed ID: 22074550 [TBL] [Abstract][Full Text] [Related]
54. An engineered antibody-interleukin-12 fusion protein with enhanced tumor vascular targeting properties. Gafner V; Trachsel E; Neri D Int J Cancer; 2006 Nov; 119(9):2205-12. PubMed ID: 16823838 [TBL] [Abstract][Full Text] [Related]
55. Antibody-mediated delivery of interleukin 4 to the neo-vasculature reduces chronic skin inflammation. Hemmerle T; Zgraggen S; Matasci M; Halin C; Detmar M; Neri D J Dermatol Sci; 2014 Nov; 76(2):96-103. PubMed ID: 25190364 [TBL] [Abstract][Full Text] [Related]
56. Potential therapeutic antibodies targeting specific adiponectin isoforms in rheumatoid arthritis. Lee YA; Hahm DH; Kim JY; Sur B; Lee HM; Ryu CJ; Yang HI; Kim KS Arthritis Res Ther; 2018 Oct; 20(1):245. PubMed ID: 30376894 [TBL] [Abstract][Full Text] [Related]
57. Antibody-based delivery of interleukin-9 to neovascular structures: Therapeutic evaluation in cancer and arthritis. Gouyou B; Ongaro T; Cazzamalli S; De Luca R; Kerschenmeyer A; Valet P; Villa A; Neri D; Matasci M Exp Biol Med (Maywood); 2021 Apr; 246(8):940-951. PubMed ID: 33475433 [TBL] [Abstract][Full Text] [Related]
58. The immunosuppressant LF 15-0195 prevents collagen-induced arthritis with IL-10 down-regulation. Ducoroy P; de Fornel D; Chirade F; Fontet P; Dutartre P Transplant Proc; 2001 May; 33(3):2142-5. PubMed ID: 11377480 [No Abstract] [Full Text] [Related]